Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-HER2 CAR macrophages CT-0508

A preparation of autologous macrophages transduced with the adenoviral vector Ad5f35 to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), with potential immunostimulatory and antineoplastic activities. Upon administration, autologous anti-HER2 CAR Macrophages (CAR-M) CT-0508 specifically recognize and bind to HER2-expressing tumor cells, resulting in the phagocytosis of HER2-expressing tumor cells. CAR-M CT-0508 maintain the pro-inflammatory, anti-tumor M1 phenotype within the human tumor microenvironment (TME). In addition, CAR-M CT-0508 may activate an anti-tumor T-lymphocyte immune response resulting in T-cell-mediated killing of tumor cells. HER2, a receptor tyrosine kinase that is mutated or overexpressed in many tumor cell types, plays an important role in tumor cell proliferation and tumor vascularization.
Synonym:autologous Ad5f35-transduced anti-HER2 CAR-M CT-0508
autologous anti-HER2 CAR-M CT-0508
autologous anti-HER2-CAR-expressing macrophages CT-0508
CAR-M CT-0508
Code name:CT 0508
CT-0508
CT0508
Search NCI's Drug Dictionary